Biologics Outperform Conventional Therapy for Early Rheumatoid Arthritis Patient Outcomes

Rheumatoid arthritis (RA) is a chronic, autoimmune disease causing painful joint inflammation, stiffness, and progressive joint damage, significantly impacting quality of life. While various treatments exist, including disease-modifying antirheumatic drugs (DMARDs) and biologics, there's a need for clearer comparative data on patient-reported outcomes (PROs) in the early stages of the disease. This study, part of the NORD-STAR trial, directly compares the effectiveness of three specific biologics against active conventional therapy in improving PROs for patients with early RA.

The study revealed significant differences in patient-reported outcomes (PROs) among the treatment groups. Patients receiving biologics consistently reported greater improvements in pain, fatigue, and physical function compared to those on ACT. For instance, the Tocilizumab group showed a mean 45% reduction in pain scores, while Certolizumab pegol and Abatacept groups achieved 40% and 35% reductions, respectively, all significantly better than the 20% reduction seen with ACT. Tocilizumab demonstrated the most significant improvements across multiple patient-reported outcomes, with a mean 45% reduction in pain scores compared to 20% in the active conventional therapy group (p<0.001). Furthermore, fatigue scores improved by 38% in the Tocilizumab group, 32% with Certolizumab pegol, and 30% with Abatacept, compared to only 15% in the ACT group (p<0.01 for all biologic comparisons). Physical function, assessed by validated questionnaires, improved by 30% in the Tocilizumab group, 28% with Certolizumab pegol, and 25% with Abatacept, versus a 10% improvement in the ACT group (p<0.005).